

# Hospital Antibiotic Use during COVID-19 Pandemic in Italy

Alessandro Perrella <sup>1,\*</sup>, Filomena Fortinguerra <sup>2,\*</sup>, Andrea Pierantozzi <sup>2</sup>, Nicolina Capoluongo <sup>1</sup>, Novella Carannante <sup>1</sup>, Andrea Lo Vecchio <sup>3</sup>, Francesca Futura Bernardi <sup>4</sup>, Francesco Trotta <sup>2</sup> and Agnese Cangini <sup>2</sup>

<sup>1</sup> I Division Emerging Infectious Disease and High Contagiousness, D. Cotugno Hospital, Naples, Italy

<sup>2</sup> Italian Medicines Agency (AIFA), Rome, Italy


<sup>3</sup> Pediatric Unit, AOU Federico II Medical School University, Naples, Italy

<sup>4</sup> Pharmacy Unit, Vanvitelli University, Naples, Italy


\* Correspondence: alessandro.perrella@ospedalideicolli.it (A.P.); f.fortinguerra@aifa.gov.it (F.F.)

## Supplementary Materials


**Figure S1** Correlation between consumption (DDD) of antibiotics for systemic use (J01) in the hospital setting and number of hospitalisation with COVID-19 symptoms and in intensive care in 2020 (*r di Pearson hospitalisation with COVID-19 symptoms: 0.82; r di Pearson intensive care: 0.87*)




**Figure S2** Correlation between consumption (DDD) of third generation cephalosporins (J01DD) in the hospital setting and number of hospitalisations with COVID-19 symptoms and in intensive care in 2020 (*r di Pearson hospitalisations with COVID-19 symptoms: 0.88; r di Pearson intensive care: 0.91*)



**Figure S3** Correlation between consumption (DDD) of carbapenems (J01DH) in the hospital setting and number of hospitalisations with COVID-19 symptoms and in intensive care in 2020 (*r di Pearson hospitalisations with COVID-19 symptoms: 0.16; r di Pearson intensive care: 0.29*)



**Figure S4** Correlation between consumption (DDD) of macrolides (J01FA) in the hospital setting and number of hospitalisations with COVID-19 symptoms and in intensive care in 2020 (*r di Pearson hospitalisations with COVID-19 symptoms: 0.73; r di Pearson intensive care: 0.79*)



**Figure S5** Correlation between consumption (DDD) of fluoroquinolones (J01MA) in the hospital setting and number of hospitalisations with COVID-19 symptoms and in intensive care in 2020 (*r di Pearson hospitalisations with COVID-19 symptoms: 0.73; r di Pearson intensive care: 0.79*)

